NanoViricides

NNVC

Market cap $22.6M

NanoViricides (NYSE-A:NNVC) earlier this week provided an update on the advancement of its broad-spectrum antiviral candidate NV-387, outlining progress in Mpox clinical development and confirming orphan drug designation filings for multiple indications. Speaking to Proactive, CEO Dr Anil Diwan said the company has completed the full clinical trial application required to initiate a Phase 2 study of NV-387 in the Democratic Republic of Congo for Mpox.

NanoViricides has provided an update on the development of its investigational antiviral NV-387, alongside the filing of its quarterly report for the fiscal quarter ending December 31, 2025. NanoViricides said it is preparing to advance NV-387 into a Phase II clinical trial for Monkeypox (MPox) in the Democratic Republic of Congo.

NanoViricides (NYSE-A:NNVC), a clinical-stage biotechnology company developing broad-spectrum antiviral therapies, has filed for Orphan Drug Designation (ODD) with the US Food and Drug Administration (FDA) for its lead candidate NV-387 as a treatment for MPox. If granted, the designation could provide NanoViricides with tax credits for clinical trials, exemption from certain user fees, and up to seven years of market exclusivity after approval.

SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for Orphan Drug Designation (ODD) for "NV-387 as a Treatment for MPox" with the US FDA Office of Orphan Products Development (OOPD). If approved, orphan drug designation will qualify NanoViricides for incentives including: Tax credits for qualified clinical trials; Exemption from certain user fees; Potential seven years of market exclusivity after approval; according to the US FDA (https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products).

NanoViricides (NYSE-A:NNVC), a clinical-stage biotechnology company developing broad-spectrum antivirals, said on Tuesday it has filed an application with the US Food and Drug Administration (FDA) for Orphan Drug Designation for its experimental drug NV-387 as a treatment for measles. If granted, the designation would provide the company with incentives including tax credits for qualified clinical trials, exemptions from certain FDA user fees, and potential seven-year market exclusivity following approval.

SHELTON, CONNECTICUT / ACCESS Newswire / February 10, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced today that it has filed an application for "Orphan Drug Designation" (ODD) for NV-387 as a Treatment for Measles with the US FDA Office of Orphan Products Development (OOPD). If approved, orphan drug designation will qualify NanoViricides for incentives including: Tax credits for qualified clinical trials; Exemption from certain user fees; Potential seven years of market exclusivity after approval; According to the US FDA (https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/designating-orphan-product-drugs-and-biological-products).

SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that our President Dr. Anil R. Diwan was interviewed on the Mission Matters Podcast by Mr.

NanoViricides (NYSE-A:NNVC), a clinical-stage company developing broad-spectrum antiviral drugs, has highlighted the current influenza season as an example of the need for antivirals capable of targeting multiple respiratory viruses. The US Centers for Disease Control and Prevention (CDC) has classified the 2025 to 2026 flu season as “moderately severe,” with the Influenza A/H3N2 subclade K responsible for more than 80% of cases.

SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, declares that the current severe influenza wave demonstrates the clear need for broad-spectrum antivirals that can work against all influenza viruses, as well as the seasonal respiratory viruses including RSV and Coronaviruses. This year has been a "moderately severe" flu season according to CDC.

NanoViricides (NYSE-A:NNVC) is gearing up to tackle multiple viral threats with Phase 2 trials for its broad-spectrum antiviral NV-378, as analysts at Alliance Global Partners kick off coverage with a Buy rating and $6 price target. The biotechnology company, which is developing innovative antiviral therapies, is advancing its lead candidate NV-378 into Phase 2 trials next year, targeting a range of viral infections including Mpox, influenza, COVID-19, and respiratory syncytial virus (RSV), according to analysts at Alliance Global Partners.